Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting

Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting

Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors

Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia's continued momentum

Shareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at assistance@laurelhill.com .

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced that Glass Lewis & Co. ("Glass Lewis"), a leading independent proxy advisor, has recommended that Aurinia shareholders vote FOR ALL proposals at the Company's 2023 Annual General Meeting (the "Meeting"), including the re-election to the Board of Directors (the "Board") of all eight incumbent directors and the approval of the Company's say-on-pay resolution.

Glass Lewis is an independent proxy advisor to institutional investors, covering 30,000 shareholder meetings each year, across approximately 100 global markets. Their customers include the majority of the world's largest pension plans, mutual funds, and asset managers who collectively manage over $40 trillion in assets.

The Board encourages all shareholders eligible to vote at the Meeting to do so today using the instructions provided below.

The virtual-only meeting will be held via live audio webcast online using the LUMI meeting platform at https://web.lumiagm.com/467056294 (password (case sensitive): aurinia2023) on Wednesday, May 17, 2023 at 12:00 pm, Eastern Time.

Aurinia has the right Board and management team to drive continued momentum and enhance shareholder value.

Our Board and management team have the right skills and expertise to continue to unlock value for all shareholders. Each director brings deep expertise in areas critical to the growth of our business, including the commercialization of pharmaceutical and biotech products, business development, and international pharmaceutical operations. Additionally, five of our eight directors bring R&D experience, six have clinical development expertise, and four have served in c-suite roles.

Aurinia's Board and management team remain focused on building upon the recent and growing momentum in the LUPKYNIS ® (voclosporin) business:

  • Increased net sales more than 194% in 2022.
  • Continued progress in key commercial areas of growth in patient start forms, faster conversion rates (time it takes to get a patient on therapy), improved adherence, and persistency (duration of therapy) rates in support of LN patients on therapy.
  • Patients on therapy continue to grow quarter-on-quarter since launch.
  • Recently issued a new method of use patent (U.S. Patent No. 11,622,991) for LUPKYNIS, adding intellectual property protection out to 2037 in the U.S.
  • Achieved numerous milestones in the globalization of LUPKYNIS in partnership with Otsuka, including approvals in the UK and EU, launches in several EU countries and regulatory filings in Japan.

Our executive compensation aligns pay with performance to support continued value creation.

Our Compensation Committee, which is comprised entirely of independent directors, makes all compensation decisions while leveraging advice from an independent third-party compensation consultant. The Compensation Committee conducts a rigorous and thorough review of market practices, especially those of peers, the general marketplace and other industry data points to determine performance targets, pay mix and levels that will best align management's interests with those of shareholders and support continued value creation.

Over the past year Aurinia has extensively engaged with shareholders on executive compensation and other important matters. Based on these conversations, the Board made several changes to its executive compensation program, including:

  • Introducing a share ownership policy for our directors and executive officers;
  • Adopting a clawback policy for our executive officers; and
  • Incorporating performance-based metrics into the annual equity grants for executives.

AURIANA SHAREHOLDERS: PROTECT THE VALUE OF YOUR INVESTMENT BY VOTING ONLINE, BY MAIL, OR TELEPHONE TODAY.

How to Vote

Shareholders of record of the Company's common shares at the close of business on April 12, 2023 may vote online at the Meeting, vote by proxy by mail, over the telephone or through the Internet.

  • To vote by mail using the proxy card, simply complete, sign and date the proxy card delivered to you and return it promptly in the envelope provided. If you return your signed proxy card to us before the Meeting by 12:00 p.m. (Eastern Time) on May 15, 2023, or no later than 48 hours (excluding Saturdays, Sundays, and holidays) before any adjournment or postponement of the Meeting, we will vote your shares as you direct.
  • To vote over the telephone , dial toll-free 1-866-732-8683 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the proxy card.
  • To vote through the Internet , go to www.investorvote.com to complete an electronic proxy card. You will be asked to provide the control number from the proxy card.

Questions or Require Voting Assistance?

Contact our proxy solicitation agent, Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at assistance@laurelhill.com .

About LUPKYNIS

LUPKYNIS ® is the first U.S. FDA- and EC-approved oral medicine for the treatment of adult patients with active LN. LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia's proprietary personalized eGFR-based dosing protocol. Boxed Warning, warnings, and precautions for LUPKYNIS are consistent with those of other CNI-immunosuppressive treatments.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company's head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

Investors:
Aurinia@westwicke.com

News Provided by Business Wire via QuoteMedia

AUPH
The Conversation (0)
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC).

Under U.S. federal securities laws, equity awards issued as employee compensation must be registered under the Securities Act of 1933, as amended, via an S-8 registration statement or qualify for an exemption from registration. This Form S-8 registers previously issued and disclosed stock options and restricted stock units (RSUs) that were granted as inducement awards to employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Announces 2023 Annual General Meeting Results

Aurinia Announces 2023 Annual General Meeting Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced voting results for its annual general meeting (the "Meeting") of shareholders held on May 17, 2023.

Shareholders re-elected six of eight incumbent directors to the Board of Directors (the "Board"). Two directors, George Milne and Joseph ("Jay") Hagan, while elected under applicable corporate law, received less than majority support and have submitted their resignations for consideration by the Board, pursuant to the Company's Majority Voting Policy. In accordance with the policy, the Board intends to act expeditiously in respect to the submitted resignations to ensure an orderly transition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS®  AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin)

Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year

Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®  For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including mixed class III/V and IV/V) 1 , when provided in combination with mycophenolate mofetil (MMF).

The NICE recommendation applies to England and Wales and follows the recent Medicines and Healthcare Products Regulatory Agency (MHRA) authorization of voclosporin licensed in Great Britain for the treatment of active LN in adult patients.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Hydralyte

Execution of Variation to Facility Agreement with PURE Asset Management, Company to Seek a Sale Transaction

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) advises that today it has signed a variation to its facility agreement with boutique asset manager and existing substantial shareholder PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (PURE or PURE Asset Management) as previously announced to the market on 17 October 2022 (Original PURE Facility).

Keep reading...Show less

Viemed Healthcare Announces Record 2023 Financial Results

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2023.

Operational highlights (all dollar amounts are USD):

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Hydralyte

Appendix 4E – Preliminary Final Report

Hydration solutions company, The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”), is pleased to report on its activities and cash flows for the 12 months ending 31 December 2023 (FY2023).

Keep reading...Show less
Hand reaching out to healthcare symbols.

Healthcare Stocks: 5 Biggest Companies in 2024

Healthcare is one of the world's most critical sectors, and healthcare stocks offer an opportunity to invest in companies that are making a difference in people’s lives while also providing a steady stream of returns.

Healthcare companies operate in a highly competitive, highly regulated environment. Often at the forefront of innovation in medicine and healthcare technology, the sector has seen a boom of activity in recent years, driven in part by advancements in technology, namely artificial intelligence, machine learning and quantum computing.

Here the Investing News Network has rounded up the biggest healthcare stocks by market cap. Data was collected using TradingView’s stock screener and was accurate as of February 7, 2024.

Keep reading...Show less
Hydralyte

Q4 FY23 Quarterly Report and Appendix 4C: Net Cash Used in Operating Activities Down 56% YoY to Record Low

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte” or “the Company”) is pleased to provide the following update on its operational and financial performance for the three-month period ended 31 December 2023 (the “quarter”).
Keep reading...Show less
  Tryp Therapeutics Inc

Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan

Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of Michigan in a collaboration with Tryp Therapeutics. The clinical trial is evaluating Tryp's TRP-8802 in patients with fibromyalgia.

Keep reading...Show less

Latest Press Releases

Related News

×